Ocugen
Market cap $257M 339.3M shares (10-Q, Oct 30, 2026) × $0.757 close Nov 17, 2026
Most recent annual filing: 2026-03-04
- Proposal 1 vote FDA decisionDec 22, 2026Proposal 1 vote FDA decision, Dec 22, 2026, material
- Reserved Share Proposal corporate updateDec 22, 2026Reserved Share Proposal corporate update, Dec 22, 2026, routine
- Governance/Authorized Shares corporate updateDec 22, 2026Governance/Authorized Shares corporate update, Dec 22, 2026, routine
- Corporate governance / cap tableDec 22, 2026Corporate governance / cap table, Dec 22, 2026, routine
- OCU400 Ph3 topline1Q 2027OCU400 Ph3 topline, 1Q 2027, thesis-defining
- Bahamas early-access program corporate update~Jan 2027Bahamas early-access program corporate update, ~Jan 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (12 active programs)
OCU410ST
OCU410
OCU200
NeoCart
- Knee Cartilage Injuries
OCU500
OCU510
OCU520
Technology platforms
Novel Modifier Gene Therapy Platform · CanSino Biologics
Nuclear hormone receptor (NHR)-based modifier gene therapy platform using AAV5 vector delivery to retinal tissue; targets NR2E3 and RORA to address multiple inherited retinal diseases including retinitis pigmentosa, Stargardt disease, and dry AMD/geographic atrophy with a gene-agnostic approach
Targets: NR2E3, RORA
Inhaled Mucosal Vaccine Platform · Washington University in St. Louis
Next-generation inhalation-based mucosal vaccine platform based on a novel ChAd vector; designed to generate local mucosal immunity in the nasopharyngeal region for respiratory infectious diseases including COVID-19 and influenza
Targets: SARS-CoV-2 Spike protein, influenza
modifier gene therapy platform
Gene-agnostic modifier gene therapy platform designed to address underlying disease biology and restore balance across multiple gene networks, enabling treatment of large patient populations with inherited retinal diseases and other causes of blindness including retinitis pigmentosa, Stargardt disease, and geographic atrophy/dry AMD
Targets: NR2E3
Inhaled Mucosal Vaccine Platform · National Institute of Allergy and Infectious Diseases
Next-generation inhaled mucosal vaccine platform; focus area: infectious diseases including COVID-19
Capital (as filed)
- Cash
- $24.6M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $59.6M Sep 30, 2026
- Operating cash flow
- −$15.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $84.6M cash, runway 2028 per the update of Nov 4, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (18)
- 2026-11-05 UPDATE: Ocugen (OCGN) - The Loss That Shrank Because the Stock Fell 🔒 Paid
- 2026-10-16 UPDATE: Ocugen (OCGN) - The Vote Slips to December 🔒 Paid
- 2026-10-07 UPDATE: Ocugen (OCGN) - Adjourned Again 🔒 Paid
- 2026-09-23 UPDATE: Ocugen (OCGN) - The Unlock Gets Postponed 🔒 Paid
- 2026-09-02 UPDATE: Ocugen (OCGN) – First Patient Dosed in ArMaDa3 🔒 Paid
- 2026-08-07 UPDATE: Ocugen (OCGN) – The Rolling BLA Rolls Away 🔒 Paid
- 2026-07-30 UPDATE: Ocugen (OCGN) – RMAT Lands, BlackRock Shows Up, Stock Doesn’t Care 🔒 Paid
- 2026-07-13 UPDATE: Ocugen (OCGN) – The Second Regional Deal Lands 🔒 Paid
- 2026-06-11 UPDATE: Ocugen (OCGN) – The Annual Meeting That Didn’t Mention the Reverse Split 🔒 Paid
- 2026-05-15 UPDATE: Ocugen (OCGN) – The Greenshoe Gets Pulled, The CMO Walks 🔒 Paid
- 2026-05-06 UPDATE: Ocugen (OCGN) – The Convert Prices, The Arb Sells, The Stock Bleeds 🔒 Paid
- 2026-05-04 UPDATE: Ocugen (OCGN) – The Fortress Gets Built (On Borrowed Bricks)
- 2026-04-27 UPDATE: Ocugen (OCGN) – The Reverse Split Cometh 🔒 Paid
- 2026-03-29 UPDATE: Ocugen (OCGN) - Phase 2 GA Data Drops – The Receipts Are In 🔒 Paid
- 2026-03-22 UPDATE: Ocugen (OCGN) – The Smart Money Shrugs Off the Delaware Drama 🔒 Paid
- 2026-03-08 UPDATE: Ocugen (OCGN) – 2025 Fiscal Year Update 🔒 Paid
- 2026-01-22 CORRECTION & UPDATE: Ocugen (OCGN) Pays the Piper
- 2026-01-21 Ocugen inc. (OCGN): Scientific Deep Dive for OCU400 and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (18 calls)
Every verdict Biotech Distilled has published on Ocugen, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-01-21 Watch Ocugen inc. (OCGN): Scientific Deep Dive for OCU400 and Pipeline Products High-conviction science shackled to a distressed balance sheet; most investors should wait for a capital raise and dilution overhang to clear before entering.
- 2026-01-22 Speculative buy speculative CORRECTION & UPDATE: Ocugen (OCGN) Pays the Piper Clean $22.5M common stock raise with no warrants removes immediate bankruptcy risk and warrant overhang, improving risk/reward for aggressive traders playing near-term data catalysts.
- 2026-03-08 Speculative buy speculative UPDATE: Ocugen (OCGN) – 2025 Fiscal Year Update Clinical thesis intact with imminent Phase 2 GA data as a major binary catalyst, but Delaware Chancery Court cap-table chaos is a severe distraction until the May 6 hearing resolves.
- 2026-03-22 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Smart Money Shrugs Off the Delaware Drama Institutional warrant exercise of $15M mid-Delaware-chaos signals the legal issue is a formality, extends runway into Q1 2027, and refocuses attention on imminent clinical readouts.
- 2026-03-29 Speculative buy speculative UPDATE: Ocugen (OCGN) - Phase 2 GA Data Drops – The Receipts Are In Full Phase 2 OCU410 data showing 31% lesion reduction with clean safety profile profoundly de-risks the science thesis, making OCU410 a premier M&A target, though Delaware legal overhang persists until May.
- 2026-04-27 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Reverse Split Cometh Clinical thesis compounding on every shot on goal while governance shadow grows; smart money signals (Millennium 5.2%, RTW, Janus Henderson) confirm conviction ahead of May 6 Delaware ruling and June 11 annual meeting.
- 2026-05-04 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Fortress Gets Built (On Borrowed Bricks) $115M+ convertible offering kills Avenue debt and extends runway plausibly into 2028, transforming the distressed balance sheet into a genuine fortress while science continues to compound.
- 2026-05-06 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Convert Prices, The Arb Sells, The Stock Bleeds The 19.5% stock drop on convertible pricing is mechanical arb-driven selling, not fundamental repricing; financing risk is now bounded and the science is unchanged, making the drawdown a potential entry point.
- 2026-05-15 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Greenshoe Gets Pulled, The CMO Walks Full $130M greenshoe exercise confirms institutional conviction while abrupt CMO departure two months before rolling BLA initiation adds a new governance question that warrants monitoring but not panic.
- 2026-06-11 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Annual Meeting That Didn't Mention the Reverse Split Genead made permanent CMO closes one open question, but the conspicuous absence of Proposal 5 (reverse split) results leaves the convertible's stock-settlement mechanics and CEO comp penalty unresolved.
- 2026-07-13 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Second Regional Deal Lands MENA regional OCU400 deal with 22% royalty and supply contract confirms the partnership playbook is working and negotiating leverage has improved post-convertible, while Proposal 5 silence now a month old.
- 2026-07-30 Speculative buy speculative UPDATE: Ocugen (OCGN) – RMAT Lands, BlackRock Shows Up, Stock Doesn't Care FDA RMAT designation for OCU410 independently validates the Phase 2 clinical signal and accelerates the regulatory path, while BlackRock's 8% stake is the sixth smart-money signal, though Proposal 5 silence now 48 days old remains the key overhang.
- 2026-08-07 Speculative buy speculative UPDATE: Ocugen (OCGN) – The Rolling BLA Rolls Away Delaware legally resolved and September 21 reserved-share vote date finally announced, but OCU400 rolling BLA reframed to post-Phase 3 topline, removing the key Q3 de-risking waypoint and extending the data gap to Q1 2027.
- 2026-09-02 Speculative buy speculative UPDATE: Ocugen (OCGN) – First Patient Dosed in ArMaDa3 ArMaDa3 Phase 3 first patient dosed on schedule confirms operational execution, but September 21 reserved-share vote remains the gating structural event before the Q1 2027 binary readout.
- 2026-09-23 Watch UPDATE: Ocugen (OCGN) - The Unlock Gets Postponed September 21 reserved-share vote adjourned without passing, stock sitting on Nasdaq's $1.00 minimum bid, and management has now failed twice to close a needed shareholder vote, warranting a downgrade to Watch until October 5 resolves the issue.
- 2026-10-07 Watch UPDATE: Ocugen (OCGN) - Adjourned Again Second adjournment of the authorized-share vote with the same electorate that couldn't pass it, while the December 31 CEO penalty deadline draws closer; October 26 is now the deciding event.
- 2026-10-16 Avoid UPDATE: Ocugen (OCGN) - The Vote Slips to December Third delay of the authorized-share vote to December 22 — nine days before the CEO cash-settlement deadline — combined with stock falling below Nasdaq's $1.00 minimum bid triggers the explicit downgrade condition set on October 6.
- 2026-11-05 Avoid UPDATE: Ocugen (OCGN) - The Loss That Shrank Because the Stock Fell Q3 confirms September vote failed outright, revived class action adds litigation risk, and the headline net loss improvement is an accounting artifact of the stock falling; December 22 vote remains the only gate for reversing the stance.
- Long call · opened Jan 22, 2026 at $1.65 · closed Sep 24, 2026 (downgraded to WATCH from long) at $1.00 · -39.4% vs XBI +18.6%
- Avoid call · opened Oct 16, 2026 at $0.780 · -2.9% vs XBI +0.7% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (6 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical trial with a topline data readout expected in the first quarter of 2027, followed by global regulatory submissions, including a Biologics License Application in the U.S. and a Marketing Authorization Application in Europe.”
matched to OCU400 · topline data
-
-
-
“Topline Phase 3 data is expected in the first quarter of 2027, advancing OCU400 towards potential approval in the fourth quarter of 2027 as a treatment option for early- to late stage RP.”
matched to OCU400 · topline data / matched to OCU400 · regulatory submission -
“We plan to initiate the Phase 3 study late in the third quarter of 2026.”
matched to OCU410 · readout other / matched to OCU410ST · interim data -
“We plan to submit a BLA for OCU410ST by mid-2027 in alignment with our strategic goal of filing three BLAs by 2028.”
matched to OCU410ST · interim data
-
-
-
“We plan to initiate the Phase 3 study late in the third quarter of 2026.”
matched to OCU410 · readout other -
“We plan to submit a BLA for OCU410ST by mid-2027 in alignment with our strategic goal of filing three BLAs by 2028.”
matched to OCU410ST · interim data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (52)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 10, 2026ReleaseOcugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
- Nov 10, 20268-KCurrent report: material agreement, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Nov 6, 2026DEFA14AProxy soliciting material
- Nov 6, 2026DEFA14AProxy soliciting material
- Nov 4, 2026ReleaseOcugen Provides Business Update with Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- Nov 4, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateOcugen's Q3 2026 earnings landed with a nearly flat net loss of $3.6M — dramatically better than the year-ago $20M — driven by a $16.6M derivative liability mark-down as the stock slid from convertible pricing levels; the December 22 authorized-share vote is confirmed; and the investor deck breaks out new OCU400 Phase 1/2 data showing 71.4% of the 7-patient ITT cohort projected to clear the Phase 3 response bar.
- Nov 4, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 29, 2026ReleaseOcugen to Participate in Upcoming November Investor and Industry Conferences
- Oct 22, 2026ReleaseOcugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
- Oct 15, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1→ BD updateThe Roots MENA deal closed as expected — but the October 26 authorized-share vote has been pushed to December 22, just nine days before the CEO letter-agreement cash penalty deadline, while OCGN bleeds below $1.00 and into Nasdaq deficiency territory. The governance hole just got much deeper.
- Oct 15, 20268-KCurrent report: material agreement, Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1→ BD updateSummary on the 8-K
- Oct 14, 2026ReleaseOcugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
- Oct 6, 2026ReleaseOcugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate→ BD updateSummary on the 8-K
- Oct 6, 20268-KCurrent report: shareholder vote→ BD updateThe authorized-share vote that was supposed to unlock the convertible's stock-settlement mechanics missed its date a third time — now adjourned to October 26 — while Ocugen simultaneously announced a European affiliate GM hire out of Amsterdam, signaling it's spending on commercialization infrastructure even as the cap table remains unresolved.
- Sep 30, 2026ReleaseOcugen to Participate in Upcoming Scientific Conferences
- Sep 29, 2026ReleaseOcugen to Participate in Upcoming October Investor and Industry Conferences
- Sep 25, 2026ReleaseOcugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
- Sep 23, 20268-KCurrent report: shareholder vote→ BD updateThe September 21 reserved-share vote the thesis has been waiting on since June 11 didn't clear — Ocugen adjourned to October 5 for another round of proxy solicitation, leaving the convertible's cash-only conversion mechanic, the going-concern tag, and the CEO's December 31 equity-settlement deadline all live for another two weeks.
- Sep 8, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- Sep 1, 2026ReleaseOcugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration→ BD updateArMaDa3 just dosed its first patient — the execution checkpoint I'd been watching since August 6 hit exactly on schedule, and Genead's Phase 3 debut lands two weeks before the September 21 reserved-share vote that could finally unlock the convertible's stock-settlement mechanics.BD extracted 1 program update from this document → OCGN pipeline
- Aug 25, 2026ReleaseOcugen to Participate in Upcoming September Investor and Industry Conferences
- Aug 14, 2026DEFA14AProxy soliciting material
- Aug 6, 2026ReleaseOcugen Provides Business Update with Second Quarter 2026 Financial ResultsBD extracted 1 program update from this document → OCGN pipeline
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- Aug 6, 202610-QQuarterly report
- Jul 31, 2026ReleaseOcugen to Participate in Upcoming August Investor Conferences
- Jul 30, 2026DEFA14AProxy soliciting material
- Jul 30, 2026DEF 14AProxy statement
- Jul 29, 2026ReleaseOcugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-RelatBD extracted 1 program update from this document → OCGN pipeline
- Jul 28, 2026ReleaseOcugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
- Jul 13, 2026ReleaseOcugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
- Jul 13, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- Jul 1, 2026ReleaseOcugen to Participate in Upcoming July Industry Conferences
- Jun 11, 20268-KCurrent report: shareholder vote, other events
- Jun 3, 20268-KCurrent report: officer / director change
- Jun 2, 2026ReleaseOcugen to Participate in Upcoming June Investor and Industry Conferences
- May 14, 2026ReleaseOcugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
- May 14, 20268-KCurrent report: officer / director change, other events
- May 14, 20268-KCurrent report: debt / obligation, unregistered sale of equity, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- May 13, 2026ReleaseOcugen to Participate in Upcoming May Scientific and Investor Conferences
- May 8, 202610-QQuarterly report
- May 7, 20268-KCurrent report: material agreement, agreement terminated, results of operations
- May 5, 20268-KCurrent report: results of operations, other events · EX-99.1 EXHIBIT 99.1
- May 4, 20268-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- Apr 28, 2026DEFA14AProxy soliciting material
- Apr 28, 2026DEF 14AProxy statement
- Mar 27, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Mar 24, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Mar 20, 20268-KCurrent report: other events
- Mar 4, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- Mar 4, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- Mar 4, 202610-KAnnual report
10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- Aug 7, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 29, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 20, 2026PRE 14APRE 14A
- Apr 28, 2026ARSAnnual report to shareholders
- Apr 20, 2026PRER14APRER14A
- Apr 17, 2026PRE 14APRE 14A
- Apr 14, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 27, 2026SCHEDULE 13G/A13G amendment
- Mar 4, 2026S-8Employee plan registration